KRAS and cancer: To translate the clinical utility of our findings in KrasG12D mice, we initially investigated the activation status of ADAM17 in human LAC patients either wild‐type or mutant for KRAS. In support of our in vivo data, significantly increased numbers (75%) of pADAM17‐expressing cells were detected in lung tumor sections of human LAC patients compared to cancer‐free controls (Fig 6A and B).